Home › NDC Lookup › Ingredients › Lamotrigine › 58437-0024-00
⚪image loading
(from DailyMed)

lamotrigine 100 mg Tablet, 7,000-count

by GlaxoSmithKline LLC · 1000 BLISTER PACK in 1 CASE (58437-024-00) / 7 TABLET in 1 BLISTER PACK
NDC 58437-0024-00
🏷️ FDA NDC (as labeled) 58437-024-00 billing pads the product segment with a zero
This package
Contains7,000-count Pack sizes2 compare ↓
Also comes in: 7000 tablets 58437-0024-01
On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 58437-024-00
Product NDC 58437-024
11-digit billing NDC 58437002400
SPL Set ID 174a9ea0-ded1-4c76-8687-81cd4c39ae0b
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-01-01
Dosage form TABLET
Substance LAMOTRIGINE
Why two NDCs? The FDA registers this code as 58437-024-00 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 58437-0024-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerGlaxoSmithKline LLC
Labeler code58437
First marketedJan 2020
Product typeDrug For Further Processing
Portfolio97 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

📗 Our plain-language guide HelloPharmacist
  • I completely understand the impatience — but the slow ramp-up is one of the most important safety steps with lamotrigine. Going too fast significantly raises your risk of a serious...
  • Why does my doctor keep telling me to increase my dose so slowly? Can't we just get to the right dose faster?
  • That's a fair question, and the honest answer is: with lamotrigine, we can't reliably tell in advance which rashes are harmless and which are dangerous. So the rule is — call your...
  • What kind of rash should I worry about? I get skin reactions from all sorts of things.
📖 Read our full Lamotrigine guide →
1
Nutrient depletion considerations

Lamotrigine may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Lamotrigine nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 7000 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Lamotrigine 100 mg 82009-0132-10 Quallent 1000 tablets $0.049 AB Availability likely —
Subvenite 100 mg 69102-0319-01 OWP 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 72888-0026-00 Advagen 1000 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 00904-7008-61 Major 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 13668-0047-01 Torrent 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 29300-0112-01 Unichem 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 65862-0228-01 Aurobindo 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 68382-0008-01 Zydus 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 16714-0195-01 Northstar 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 59746-0246-01 Jubilant 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 68084-0319-01 American 100 tablets $0.049 AB Availability likely —
Lamotrigine 100 mg 69918-0370-30 Nordic 30 tablets $1.799 AB Availability likely —
Lamotrigine 100 mg 51672-4254-06 Sun 30 tablets $1.799 AB Availability likely —
Lamictal 100 mg 00173-0642-55 GlaxoSmithKline 100 tablets $10.917 AB Availability likely —
Lamotrigine 100 mg 71205-0245-30 Proficient 30 tablets — AB FDA listed —
Lamotrigine 100 mg 46708-0275-30 Alembic 30 tablets — AB FDA listed —
Lamotrigine 100 mg 67877-0165-01 Ascend 100 tablets — AB FDA listed —
Lamotrigine 100 mg 00615-7975-39 NCS 30 tablets — AB FDA listed —
Lamotrigine 100 mg 43063-0203-30 PD-Rx 30 tablets — AB FDA listed —
Lamotrigine 100 mg 71335-0706-01 Bryant 30 tablets — AB FDA listed —
Lamotrigine 100 mg 42291-0367-01 AvKARE 100 tablets — AB FDA listed —
Lamotrigine 100 mg 50090-2130-00 A-S 30 tablets — AB FDA listed —
Lamotrigine 100 mg 62332-0038-30 Alembic 30 tablets — AB FDA listed —
Lamotrigine 100 mg 70518-2343-01 REMEDYREPACK 30 tablets — AB FDA listed —
Lamotrigine 100 mg 55154-2065-00 Cardinal 10 tablets — AB FDA listed —
Lamotrigine 100 mg 67046-0359-03 Coupler 30 tablets — AB FDA listed —
Lamotrigine 100 mg 68071-3607-06 NuCare 60 tablets — AB FDA listed —
Lamotrigine 100 mg 55111-0221-01 Dr.Reddy's 100 tablets — AB FDA listed —
Lamotrigine 100 mg 65841-0684-01 Zydus 100 tablets — AB FDA listed —
Lamotrigine 100 mg 68071-3944-06 NuCare 60 tablets — AB FDA listed —
lamotrigine 100 mgthis 58437-0024-00 GlaxoSmithKline 7000 tablets — — FDA listed —
Lamotrigine 100 mg 68788-7871-03 Preferred 30 tablets — AB FDA listed —
Lamotrigine 100 mg 72789-0206-60 PD-Rx 60 tablets — AB FDA listed —
Lamotrigine 100 mg 51672-4131-00 Sun 100 tablets — AB FDA listed —
Lamotrigine 100 mg 68071-3514-06 NuCare 60 tablets — AB FDA listed —
Lamotrigine 100 mg 82868-0005-30 Northwind 30 tablets — AB FDA listed —
Lamotrigine 100 mg 55154-2330-00 Cardinal 10 tablets — AB FDA listed —
Lamotrigine 100 mg 68788-7223-03 Preferred 30 tablets — AB FDA listed —
Lamotrigine 100 mg 70518-2563-00 REMEDYREPACK 30 tablets — AB FDA listed —
Lamotrigine 100 mg 71335-2328-01 Bryant 30 tablets — AB FDA listed —
Lamotrigine 100 mg 70518-2889-00 REMEDYREPACK 30 tablets — AB FDA listed —
Lamotrigine 100 mg 84677-0033-30 Golden 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2020
On the market since
Jan 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Lamotrigine (matched by generic name) — the program that covers self-administered drugs. 15 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Lamotrigine. CMS lists 15 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.58M
Claims incl. refills
1.1M
Beneficiaries
533.3K
Spend / beneficiary
$31.09
Spend / claim
$15.37
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
58437-0024-00 You're viewing this 1000 BLISTER PACK in 1 CASE (58437-024-00) / 7 TABLET in 1 BLISTER PACK — Active
58437-0024-01 500 BLISTER PACK in 1 CASE (58437-024-01) / 14 TABLET in 1 BLISTER PACK — Active

Pack size FAQ

What quantity is in NDC 58437-0024-00?
NDC 58437-0024-00 is a 7,000-count package — 1000 blister pack in 1 case / 7 tablet in 1 blister pack.
What is the difference between NDC 58437-0024-00 and NDC 58437-0024-01?
Both are lamotrigine 100 mg Tablet — the drug itself is identical. NDC 58437-0024-00 is the 7,000-count package, while NDC 58437-0024-01 is the 7000 tablets package.
What NDC number is used to bill for this package of lamotrigine 100 mg Tablet?
Bill NDC 58437-0024-00 — the 11-digit billing format is 58437002400. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

🧭 About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: GlaxoSmithKline LLC supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 58437-024-00, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 58437-0024-00, written without dashes as 58437002400. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 58437-0024-00, the first segment (58437) is the labeler code FDA assigned to GlaxoSmithKline LLC; the middle segment (0024) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (00) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by GlaxoSmithKline LLC. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 7000 tablets (58437-0024-01). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
GlaxoSmithKline LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 58437-0023-00 · GlaxoSmithKline 58437-0027-00 · GlaxoSmithKline →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.